22 55

Cited 0 times in

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study

 Seong Yong Park  ;  Samina Park  ;  Geun Dong Lee  ;  Hong Kwan Kim  ;  Sehoon Choi  ;  Hyeong Ryul Kim  ;  Yong-Hee Kim  ;  Dong Kwan Kim  ;  Seung-Il Park  ;  Tae Hee Hong  ;  Yong Soo Choi  ;  Jhingook Kim  ;  Jong Ho Cho  ;  Young Mog Shim  ;  Jae Ill Zo  ;  Kwon Joong Na  ;  In Kyu Park  ;  Chang Hyun Kang  ;  Young-Tae Kim  ;  Byung Jo Park  ;  Chang Young Lee  ;  Jin Gu Lee  ;  Dae Joon Kim  ;  Hyo Chae Paik 
 CANCER RESEARCH AND TREATMENT, Vol.55(1) : 94-102, 2023-01 
Journal Title
Issue Date
Aged ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Female ; Humans ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / surgery ; Male ; Middle Aged ; Neoplasm Recurrence, Local / pathology ; Neoplasm Staging ; Radiotherapy, Adjuvant ; Retrospective Studies ; Small Cell Lung Carcinoma* / drug therapy ; Small Cell Lung Carcinoma* / surgery
Adjuvant chemotherapy ; Small cell lung carcinoma ; Survival
Purpose This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.Materials and Methods The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.Results The mean patient age was 65.29 +/- 8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) under-went prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemo-therapy (HR, 0.558; p=0.019) were associated with OS.Conclusion Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.
Files in This Item:
T992023422.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dae Joon(김대준)
Park, Byung Jo(박병조)
Park, Seong Yong(박성용) ORCID logo https://orcid.org/0000-0002-5180-3853
Paik, Hyo Chae(백효채) ORCID logo https://orcid.org/0000-0001-9309-8235
Lee, Jin Gu(이진구)
Lee, Chang Young(이창영)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.